Mylan N.V. (MYL) PT Set at $32.00 by Wells Fargo & Company
MYL has been the subject of several other research reports. Cantor Fitzgerald initiated coverage on Mylan N.V. in a research report on Friday, June 16th. They issued a neutral rating and a $41.00 price target for the company. Royal Bank Of Canada set a $41.00 price target on Mylan N.V. and gave the stock a hold rating in a research report on Sunday, July 16th. BidaskClub raised Mylan N.V. from a strong sell rating to a sell rating in a research report on Thursday, September 7th. BMO Capital Markets reaffirmed a buy rating and issued a $45.00 price target on shares of Mylan N.V. in a research report on Friday, September 29th. Finally, BTIG Research lifted their price target on Mylan N.V. from $42.00 to $45.00 and gave the stock a buy rating in a research report on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company’s stock. Mylan N.V. presently has an average rating of Buy and a consensus target price of $41.21.
Shares of Mylan N.V. (MYL) traded up 0.50% during mid-day trading on Wednesday, reaching $37.95. 4,860,646 shares of the company’s stock were exchanged. The firm has a market capitalization of $20.35 billion, a P/E ratio of 30.68 and a beta of 1.30. The stock has a 50-day moving average of $33.18 and a 200 day moving average of $36.33. Mylan N.V. has a one year low of $29.39 and a one year high of $45.87.
Mylan N.V. (NASDAQ:MYL) last announced its quarterly earnings data on Wednesday, August 9th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.18 by ($0.08). The firm had revenue of $2.96 billion for the quarter, compared to analysts’ expectations of $3 billion. Mylan N.V. had a net margin of 5.51% and a return on equity of 22.42%. The business’s quarterly revenue was up 15.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.16 EPS. On average, analysts forecast that Mylan N.V. will post $4.58 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Mylan N.V. (MYL) PT Set at $32.00 by Wells Fargo & Company” was posted by Marea Informative and is owned by of Marea Informative. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at http://www.mareainformativa.com/mylan-n-v-s-myl-market-perform-rating-reaffirmed-at-wells-fargo-company/118008/.
Several institutional investors have recently added to or reduced their stakes in the business. Bellwether Investment Group LLC grew its stake in shares of Mylan N.V. by 0.3% during the 2nd quarter. Bellwether Investment Group LLC now owns 6,622 shares of the company’s stock valued at $257,000 after purchasing an additional 23 shares during the period. Suntrust Banks Inc. grew its stake in shares of Mylan N.V. by 0.7% during the 2nd quarter. Suntrust Banks Inc. now owns 9,184 shares of the company’s stock valued at $355,000 after purchasing an additional 60 shares during the period. Cleararc Capital Inc. grew its stake in shares of Mylan N.V. by 0.6% during the 1st quarter. Cleararc Capital Inc. now owns 10,394 shares of the company’s stock valued at $405,000 after purchasing an additional 67 shares during the period. Dai Ichi Life Insurance Company Ltd grew its stake in shares of Mylan N.V. by 0.4% during the 2nd quarter. Dai Ichi Life Insurance Company Ltd now owns 26,002 shares of the company’s stock valued at $1,009,000 after purchasing an additional 107 shares during the period. Finally, Sei Investments Co. grew its stake in shares of Mylan N.V. by 1.0% during the 1st quarter. Sei Investments Co. now owns 13,870 shares of the company’s stock valued at $541,000 after purchasing an additional 134 shares during the period. Institutional investors and hedge funds own 71.97% of the company’s stock.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Stock Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related stocks with our FREE daily email newsletter.